During yesterday’s Federal Trade Commission public workshop on drug pricing competition, Scott Gottlieb, MD, Commissioner of the FDA, called on drug makers to “end the shenanigans” that delay drug competition in the US marketplace.
During yesterday’s Federal Trade Commission public workshop on drug pricing competition, Scott Gottlieb, MD, Commissioner of the FDA, called on drug makers to “end the shenanigans” that delay drug competition in the US marketplace.
Gottlieb’s comment came at the same time as a statement announcing new FDA draft guidance on streamlining the submission and review process for shared-system risk evaluation and mitigation strategies (REMS) programs. While REMS are designed to protect patient safety by providing such materials as medication guides or package inserts (and requiring activities like provider training and patient counseling in some cases), REMS have come under fire as a way that makers of innovator drugs can stave off competition from generics and biosimilars. Because originator product manufacturers and biosimilar or generic drug developers must agree on a single, shared REMS system, REMS programs can potentially be abused to delay the market entry of cheaper drugs.
“Negotiations to reach agreement on shared system REMS can take extended periods of time. This can block the timely entry of a generic competitor,” said Gottlieb. “I believe branded firms sometimes use these negotiations strategically, as a way to slow generic competitors.”
“[We] need to make sure that REMS programs maintain their role in serving public health and don’t become a tool companies can use to delay or block competition from generic products entering the market,” Gottlieb continued, announcing new FDA draft guidance for industry that describes how applicants can submit drug master files, representing all participating firms, to the agency.
The draft guidance, titled “Use of a Drug Master File for Shared System REMS Submissions,” eliminates the need for each manufacturer involved in a REMS process to submit files individually, eliminates duplicative paperwork for drug makers, and streamlines the forms that the FDA’s reviewers must assess. While the new drug master file system is not mandatory, Gottlieb said that “we strongly encourage” its use.
Under the system, only 1 company will be listed as the holder of the master file, and any submission to the file will be assumed to represent the views of all participating REMS applicants. The master file holder must submit a letter of authorization that allows the FDA to review the information in the file in support of REMS applicants.
Among the materials that should be included in the file are the REMS document and materials, the REMS supporting document, REMS assessments and assessment methodologies, REMS correspondence and history, interim versions of documents, responses to the FDA’s requests for information, and file amendments.
Gottlieb also indicated that the FDA will release more information about the circumstances under which it intends to waive the requirement of a single, shared REMS system, including information about how generic drug developers can request waivers.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.